Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 734-744

  Joy, Melanie S ^a   Candiani, Corina ^a   Vaillancourt, Beverly A ^a   Chin, Hyunsook ^a   Hogan, Susan L ^a   Falk, Ronald J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Chronic kidney disease; CKD; Darbepoetin alfa; Extended dosing

Indexed keywords

FERROUS SULFATE; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHARMACIST; PRIMARY HEALTH CARE;

AGED; AMBULATORY CARE; ANEMIA; ERYTHROPOIETIN; FEMALE; FERROUS COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT CARE TEAM; PHARMACISTS; POLYSACCHARIDES; PROFESSIONAL ROLE; PROGRAM DEVELOPMENT; QUALITY ASSURANCE, HEALTH CARE;

EID: 34247860710     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.734     Document Type: Article

References (30)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population: third national health and nutrition examination survey. Am J Kidney Dis 2003;41:1-12.
2. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999-2000. J Am Soc Nephrol 2005;16:180-8.
3. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266.
5. Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 2002;11:337-41.
6. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-12.
7. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991;58:129-34.
8. Evans RW, Rader B, Manninen DL, for the Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263:825-30.
9. Marsh JT, Brown WS, Wolcott D, et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991;39:155-63.
10. Foley RN. Anaemia: cardiovascular adaptations and maladaptive responses in chronic kidney disease. Nephrol Dial Transplant 2002;17(suppl 11):32-4.
11. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14: 2919-25.
12. Goicoechea M, de Vinuesa SG, Gomez-Campdera F, Luno J. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int 2005;93(suppl):S35-8.
13. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
14. Macdougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990;335:489-93.
15. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an underrecognized and undertreated problem. Nephrol Dial Transplant 2002;17(suppl 11):44-6.
16. National Kidney Foundation. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182-238. (Erratum in Am J Kidney Dis 2001;38:442.)
17. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-145.
18. National Institutes of Health. U.S. renal data system: USRDS 2005 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
21. Amgen, Inc. Aranesp (darbepoetin alfa) United States package insert. Thousand Oaks, CA; 2005.
22. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23:106-11.
23. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453-60.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
25. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992;51:76-89.
26. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
27. Silverberg DS, Wexler D, Blum M, et al. The interaction between heart failure, renal failure and anemia: the cardio-renal anemia syndrome. Blood Purif 2004;22:277-84.
28. Mix TC, Brenner RM, Cooper ME, et al. Rationale-trial to reduce cardiovascular events with aranesp therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005;149:408-13.
29. Perlman RL, Riser M, Finkelstein F, et al. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. Semin Dial 2003;16:418-23.
30. Feldman HI, Appel LJ, Chertow GM, et al. The chronic renal insufficiency cohort (CRIC) study: design and methods. J Am Soc Nephrol 2003;14:S148-53.